MORPHEUS joins the Graphene Flagship fleet
The Graphene Flagship welcomes MORPHEUS, a new research project exploring new frontiers in hospital sensor technologies, to our fleet of two-dimensional materials (2D materials) projects.
News articles
Graphene oxide added to the composition of the liquid artificial retina: A further step toward clinical trials
Graphene Flagship partner, the Istituto Italiano di Tecnologia, together with IRCCS Azienda Ospedaliera Metropolitana – Policlinico San Martino Hospital, has demonstrated that graphene oxide—used for the first time in the ophthalmic field—enhances the liquid artificial retina, increasing light sensitivity and recovery of visual function in advanced stages of retinitis pigmentosa. The study, published in Nature Communications, led to the restoration of electrical activity in the visual cortex, bringing this strategy closer to future clinical trials in humans.
Spotlight: Teissir Ben Ammar
Bridging the gap between today’s proven advances and real, market-ready solutions.
Graphene in Sensors - the technology behind tomorrow's intelligence
If you’ve ever wondered what graphene can really do in sensing technologies, this podcast is for you.
MUNASET Publication: Graphene-Enhanced Plasmonic Interfaces
A General Strategy for Highly Sensitive Detection of Biomolecular Interactions
Melexis and Graphenea Accelerate Graphene Biosensor Development
Graphenea Semiconductor, a leading graphene foundry company and partner in the Graphene Flagship's 2D Pilot Line project and Melexis, a global supplier of micro-electronic semiconductor solutions, announces a strategic collaboration to accelerate the development and evaluation of Melexis’ integrated GFET-on-CMOS platform for advanced biosensing.
MUNASET Publication: Emergence of graphene-based biosensors for depression treatment
Recent research on various biomarkers for major depressive disorder (MDD) provide an opportunity to develop biosensors that can overcome the challenges faced by conventional diagnostic tools, MUNASET researchers say.
2D-BioPAD and MUNASET at Graphene Week 2025: Showcasing Graphene-Based Biomedical Innovation
2D-BioPAD and MUNASET at Graphene Week 2025: Showcasing Graphene-Based Biomedical Innovation
MUNASET publishes a perspective piece on graphene-based biosensors and their use in the prediction of depression
Emergence of graphene-based biosensors for improved treatment response prediction in major depressive disorder: a perspective.
Jack Maughan’s Work at the Edge of Graphene and Neuroscience
At the crossroads of cutting-edge materials science and advanced biomedical engineering, Jack Maughan is building tools that could reshape how we treat and interact with the brain. A postdoctoral researcher with a background in nanoscience and tissue engineering, Jack is exploring how graphene-based microneedles can enable next-generation neural interfaces devices that could one day treat neurological disorders, restore movement, and even enhance human-machine communication.
Enabling EU-funded project collaboration for brain health R&I
Enabling EU-funded project collaboration for brain health R&I
2D Materials Innovation for Biomedical Applications
RIA PULSE: 4 HORIZON EUROPE PROJECTS IN ACTION
2D Materials Innovation for Biomedical Applications (1)
Welcome to the world of two-dimensional (2D) materials- Materials so thin, just a few atoms thick, which makes them both exceptionally lightweight and highly versatile. Some of these materials, such as graphene, are incredible strong, flexible, excellent conductors of electricity, and have a large surface area.
2D BioPAD 4th Consortium Meeting
PRESS RELEASE - Strong collaboration among clinical, academic and industrial partners brings Europe a step closer to cost-effective point-of-care diagnostics for Alzheimer’s Disease.